EAM
ABVX

Exome Asset Management’s Abivax ABVX Stock Holding History

Exome Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25M Buy
+46,878
New +$5.31M 3.85% 7

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Exome Asset Management's ABVX Position: Q2 2026 in Review

Exome Asset Management opened a new position in Abivax (ABVX) in Q2 2026: 46,878 shares worth $6.25M. The stake represents 3.85% of the portfolio and ranks #7 among its holdings.

302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Exome Asset Management held 46,878 shares of Abivax worth $6.25M as of Q2 2026.
  • Abivax was a new Exome Asset Management position in Q2 2026.
  • Abivax made up 3.85% of Exome Asset Management's portfolio in Q2 2026, its #7 holding.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.